Literature DB >> 25120851

Clinicopathological and prognostic significance of microRNA-107 in human non small cell lung cancer.

Kai-Ze Zhong1, Wei-Wen Chen2, Xiao-Yan Hu2, An-Li Jiang2, Jian Zhao1.   

Abstract

BACKGROUND: MicroRNAs (miRNAs) are small, non-coding RNAs which can function as oncogenes or tumor suppressor genes in human cancers. Researchers have found that the expression level of miR-107 was decreased in human non-small cell lung cancer (NSCLC) tissues and cell lines, however, its clinicopathological and prognostic significance in NSCLC has not been investigated.
METHODS: Quantitative real-time PCR (qRT-PCR) was used to analyze the expression of miR-107 in 137 pairs of fresh NSCLC and matched adjacent normal tissue specimens. The chi-square test and Fishers exact tests were used to examine the associations between miR-107 expression and the clinicopathological characters. The overall survival (OS) and progression-free survival (PFS) were analyzed by log-rank test, and survival curves were plotted according to Kaplan-Meier.
RESULTS: The expression level of miR-107 was significantly lower in tumor tissues than that in corresponding noncancerous tissues (0.4676 ± 0.2078 vs. 1.000 ± 0.3953, P<0.001). Low expression of miR-107 was found to significantly correlate with TNM stage (p=0.001), regional lymph node involvement (p=0.04), and tumor differentiation (p=0.003). Kaplan-Meier analysis with the log-rank test indicated that low miR-107 expression had a significant impact on OS (35.2% vs. 69.3%; P=0.008) and PFS (30.0% vs. 56.2%; P=0.029). In a multivariate Cox model, we found that miR-107 expression was an independent poor prognostic factor for both 5-year OS (HR=2.57, 95% CI: 1.88-10.28; P=0.007) and 5-year PFS (HR=3.08, 95% CI: 2.01-8.92; P=0.003).
CONCLUSION: The expression of miR-107 was decreased in NSCLC. Low expression of miR-107 was significantly associated with tumor progression and decreased survival in patients with NSCLC, indicating that miR-107 may serve as a novel prognostic marker in NSCLC.

Entities:  

Keywords:  MicroRNA-107; non-small cell lung cancer; prognosis

Mesh:

Substances:

Year:  2014        PMID: 25120851      PMCID: PMC4129086     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  23 in total

1.  Discordant expression of miR-103/7 and pantothenate kinase host genes in mouse.

Authors:  Brenda J Polster; Shawn K Westaway; Thuy M Nguyen; Moon Y Yoon; Susan J Hayflick
Journal:  Mol Genet Metab       Date:  2010-08-04       Impact factor: 4.797

Review 2.  Pathogenesis of lung cancer: 100 year report.

Authors:  York E Miller
Journal:  Am J Respir Cell Mol Biol       Date:  2005-09       Impact factor: 6.914

3.  MiRNA-107 inhibits proliferation and migration by targeting CDK8 in breast cancer.

Authors:  Xiao-Yu Li; Qi-Feng Luo; Chuan-Kui Wei; Deng-Feng Li; Jia Li; Lin Fang
Journal:  Int J Clin Exp Med       Date:  2014-01-15

4.  Toll-like receptor-4 (TLR4) down-regulates microRNA-107, increasing macrophage adhesion via cyclin-dependent kinase 6.

Authors:  Elizabeth J Hennessy; Frederick J Sheedy; David Santamaria; Mariano Barbacid; Luke A J O'Neill
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

5.  miR-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells.

Authors:  Li Feng; Yun Xie; Hao Zhang; Yunlin Wu
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

Review 6.  MicroRNA control of signal transduction.

Authors:  Masafumi Inui; Graziano Martello; Stefano Piccolo
Journal:  Nat Rev Mol Cell Biol       Date:  2010-03-10       Impact factor: 94.444

Review 7.  MicroRNA in lung cancer.

Authors:  P-Y Lin; S-L Yu; P-C Yang
Journal:  Br J Cancer       Date:  2010-09-21       Impact factor: 7.640

8.  The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1.

Authors:  Wang-Xia Wang; Bernard W Rajeev; Arnold J Stromberg; Na Ren; Guiliang Tang; Qingwei Huang; Isidore Rigoutsos; Peter T Nelson
Journal:  J Neurosci       Date:  2008-01-30       Impact factor: 6.167

Review 9.  An emerging place for lung cancer genomics in 2013.

Authors:  Marissa G Daniels; Rayleen V Bowman; Ian A Yang; Ramaswamy Govindan; Kwun M Fong
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 10.  MicroRNAs-role in lung cancer.

Authors:  Małgorzata Guz; Adolfo Rivero-Müller; Estera Okoń; Agnieszka Stenzel-Bembenek; Krzysztof Polberg; Maria Słomka; Andrzej Stepulak
Journal:  Dis Markers       Date:  2014-03-13       Impact factor: 3.434

View more
  15 in total

1.  miR-15b regulates cisplatin resistance and metastasis by targeting PEBP4 in human lung adenocarcinoma cells.

Authors:  Z Zhao; L Zhang; Q Yao; Z Tao
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

2.  Associations of deregulation of mir-365 and its target mRNA TTF-1 and survival in patients with NSCLC.

Authors:  Ruifang Sun; Zhigang Liu; Gang Ma; Weidong Lv; Xinliang Zhao; Guangyan Lei; Changfu Xu
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

3.  Role of microRNA-4458 in patients with non-small-cell lung cancer.

Authors:  Lidao Bao; Linlin Wang; Guomin Wei; Yuehong Wang; Gerile Wuyun; Agula Bo
Journal:  Oncol Lett       Date:  2016-09-22       Impact factor: 2.967

4.  Decreased expression of microRNA-107 predicts poorer prognosis in glioma.

Authors:  Yuchen Ji; Yujun Wei; Jianyong Wang; Qiang Ao; Kai Gong; Huancong Zuo
Journal:  Tumour Biol       Date:  2015-01-18

5.  miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers.

Authors:  J Remon; D Alvarez-Berdugo; M Majem; T Moran; N Reguart; P Lianes
Journal:  Clin Transl Oncol       Date:  2015-07-22       Impact factor: 3.405

Review 6.  Epigenetics in non-small cell lung cancer: from basics to therapeutics.

Authors:  Junaid Ansari; Rodney E Shackelford; Hazem El-Osta
Journal:  Transl Lung Cancer Res       Date:  2016-04

7.  MicroRNA-107 inhibits tumor growth and metastasis by targeting the BDNF-mediated PI3K/AKT pathway in human non-small lung cancer.

Authors:  Huan Xia; Yang Li; Xiaohong Lv
Journal:  Int J Oncol       Date:  2016-07-25       Impact factor: 5.650

8.  Analysis of microRNA (miRNA) expression profiles reveals 11 key biomarkers associated with non-small cell lung cancer.

Authors:  Ke Wang; Mingwei Chen; Wei Wu
Journal:  World J Surg Oncol       Date:  2017-09-19       Impact factor: 2.754

9.  Circulating plasma microRNAs as potential markers to identify EGFR mutation status and to monitor epidermal growth factor receptor-tyrosine kinase inhibitor treatment in patients with advanced non-small cell lung cancer.

Authors:  Lili Qu; Liangliang Li; Xiaofei Zheng; Hanjiang Fu; Chuanhao Tang; Haifeng Qin; Xiaoyan Li; Hong Wang; Jianjie Li; Weixia Wang; Shaoxing Yang; Lin Wang; Guanhua Zhao; Panpan Lv; Yangyang Lei; Min Zhang; Hongjun Gao; Santai Song; Xiaoqing Liu
Journal:  Oncotarget       Date:  2017-07-11

Review 10.  MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas.

Authors:  Irina Fadejeva; Horst Olschewski; Andelko Hrzenjak
Journal:  Oncotarget       Date:  2017-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.